TrialJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2019

Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.

Benjamin Z Leder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.